Federal Register: FDA · October 7, 2026 · Primary source
Determination That Oxandrin (Oxandrolone) Tablets, 2.5 Milligrams and 10 Milligrams, Were Withdrawn From Sale for Reasons of Safety or Effectiveness; Correction
Read the full document at Federal Register: FDA.
Related items
- Federal Register: FDA · October 21, 2026Regulatory Considerations for Prescription Drug Use-Related Software; Guidance for Industry; AvailabilityScore 51
- Federal Register: FDA · October 16, 2026Electronic Common Technical Document (eCTD); Data Standards; Supporting Forward Compatibility for eCTD 4.0Score 30
- Federal Register: FDA · October 15, 2026Authorization of Emergency Use for Four Animal Drugs for the Prevention and Treatment of New World Screwworm; AvailabilityScore 28
- Federal Register: FDA · October 9, 2026Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Expanded Access to Investigational Drugs for Treatment UseScore 28
- Federal Register: FDA · October 16, 2026Fit-for-Purpose Rare Disease Framework Initiative; Public Meeting; Request for Information and CommentsScore 26
- Federal Register: FDA · October 16, 2026Electronic Common Technical Document; Data Standards; Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research Supporting Electronic Common Technical Document Version 3.2.2 and Version 4.0Score 26